RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) granted stock options and restricted stock units covering a combined 26,040 shares to a new non-executive employee as an employment inducement under Nasdaq rules.
The Radnor-based biopharmaceutical company granted an option covering 14,880 common shares and restricted stock units covering another 11,160 shares on Sept. 21.
The awards were made under Mineralys’ 2025 Employment Inducement Incentive Award Plan and were considered material to the employee accepting a position with the company. They were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the Sept. 21 vesting commencement date. The remaining shares will vest in monthly increments of 1/48th of the total award, subject to continued employment.
The restricted stock units also carry a four-year vesting schedule, with 25% vesting on each of the first four anniversaries of the commencement date, subject to continued service.
Mineralys develops treatments targeting hypertension and related conditions associated with dysregulated aldosterone, including chronic kidney disease and obstructive sleep apnea.
Its lead product candidate, lorundrostat, is an investigational oral aldosterone synthase inhibitor. Mineralys was founded by Catalys Pacific and is based in Radnor.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.